Top 50 Digital Therapeutics

The startup develops prescription digital therapeutics that utilize evidence-based methodologies to provide patients with structured, interactive treatment programs for chronic illnesses. These digital solutions enable patients and healthcare providers to effectively manage symptoms and improve overall health outcomes.

Feel Therapeutics utilizes AI-driven algorithms to collect and analyze continuous physiological and digital data from wearables and mobile applications, generating objective biomarkers for mental health conditions such as mood, stress, and sleep. This technology enables personalized digital therapeutics and real-time interventions, enhancing patient support and engagement in mental health care.

Click Therapeutics provides FDA‑cleared prescription digital therapeutics delivered through a HIPAA‑compliant mobile app that can be linked to a partner drug’s label to create a software‑enhanced therapy. The platform includes an adaptive neuromodulatory engine, real‑time analytics, and FHIR‑compatible EHR integration, allowing clinicians to monitor outcomes and pharmaceutical companies to augment their drug portfolios. Revenue is generated via product licensing, per‑patient subscription fees, and partnership milestone and royalty agreements.

WELT develops digital biomarkers and digital therapeutics that utilize smartphone and sensor data to monitor and predict health outcomes. The platform delivers personalized therapies to manage and prevent diseases, addressing the need for effective, data-driven healthcare solutions.

This startup develops digital therapeutics using gamification to deliver personalized therapy and medication tracking for children with ADHD and/or Autism. Their platform aims to improve treatment adherence and outcomes through engaging, interactive experiences.

The startup develops a digital therapeutics platform that utilizes machine learning to enable users to self-screen for dementia, providing accessible diagnostics and care. By integrating clinical research with digital solutions, the platform aims to mitigate the risk of dementia and enhance the quality of care available to patients.

Alex Therapeutics develops AI-integrated digital therapy companions that assist patients in managing complex treatment regimens and mental health challenges associated with cancer and rare diseases. Their evidence-based platform enhances patient adherence to medication and therapy, leading to improved health outcomes through behavior modification.

Theranica develops prescription digital therapeutics that utilize remote electrical neuromodulation to trigger conditioned pain modulation, effectively reducing migraine pain without medication. Their wearable device, Nerivio, stimulates peripheral nerves to enhance the brain's natural pain inhibition mechanisms, providing a safe and drug-free alternative for pain management.

This startup develops B2B digital therapeutics software that operates on off-the-shelf Augmented Reality glasses, providing rehabilitation clinics with a wearable solution for both in-clinic and at-home therapy. The software enables clinics to enhance service scalability, improve patient access, and decrease neuro-rehabilitation treatment costs while reducing staff time by two-thirds.

HelloBetter provides evidence-based digital therapeutics for mental health, offering online therapy courses that are scientifically validated and available at no cost through prescriptions in Germany. The platform addresses issues such as anxiety, stress, and chronic pain by delivering structured programs guided by licensed psychologists, enhancing accessibility to mental health care for millions.

This startup develops digital medicine and digital therapeutic (DTx) solutions. Their products are clinically validated and designed for patient use.

Strolll develops augmented reality software for AR glasses that guides and empowers movement therapy. Their digital therapeutics aim to improve outcomes for individuals with neurological disorders through engaging, personalized exercises.

Neuroglee Therapeutics offers a digital therapeutic platform that provides personalized, multi-domain care plans and cognitive training for patients with mild cognitive impairment and dementia. By integrating a physician-led virtual care team and ongoing assessments, the platform enhances patient outcomes and supports caregivers in managing brain health from home.

The startup has developed a digital therapy application that provides cancer patients with tailored information on diagnosis, treatment options, nutritional guidance, and relaxation techniques. This application supports patients in managing the complexities of their illness and enhances their overall well-being through accessible digital resources.

Prosoma develops a clinically validated digital therapeutic platform, Living Well, that provides psychological and behavioral support specifically for cancer patients. This solution effectively reduces symptoms of stress, anxiety, and depression, enhancing patients' emotional well-being and overall quality of life during their treatment journey.

Mindset Health develops evidence-based digital therapeutics utilizing hypnotherapy to help individuals manage chronic health conditions such as irritable bowel syndrome, anxiety, and menopausal symptoms. Their programs provide accessible self-management tools and educational resources, enabling users to improve their well-being without reliance on medication or invasive treatments.

CureApp develops evidence-based therapeutic applications that provide personalized treatment interventions for conditions like hypertension outside traditional clinical settings. By utilizing digital therapy, the company enhances patient engagement and treatment efficacy, ensuring high-quality healthcare access for all.

The startup offers a personalized digital therapy platform that provides expert-led courses, self-management tracking, and clinical messaging for patients with inflammatory conditions. This system enables clinicians and patients to monitor health progress and gain tailored insights, improving daily health outcomes and long-term management of chronic illnesses.

Closed Loop Medicine develops personalized digital healthcare solutions that integrate dose-optimized drug therapy with digital therapeutics to enhance treatment adherence and patient outcomes. The platform addresses the inefficiencies of traditional healthcare delivery, which often leads to suboptimal management of chronic conditions and increased costs for payors.

Dawn Health develops regulated digital health products, including software as a medical device (SaMD) and digital therapeutics (DTx), to enhance chronic care management through patient empowerment and remote monitoring. Their platform accelerates the development and market entry of these solutions, improving patient adherence and outcomes while ensuring compliance with medical device regulations.

Fitterfly provides personalized digital therapeutics programs for diabetes management and weight loss, utilizing continuous glucose monitoring and data-driven lifestyle interventions. Their approach combines expert guidance in nutrition, exercise, and mental wellness to help users achieve measurable health improvements, such as an average HbA1c reduction of 1.96% and weight loss of 5 kg.

YLAH is a digital therapy platform that combines in-person psychotherapy with online therapeutic activities, facilitating a blended approach to mental health treatment. It addresses the challenge of fragmented therapy experiences by providing tools for professionals to efficiently plan, monitor progress, and engage patients between sessions.

Remepy develops hybrid drugs that integrate digital molecules with traditional pharmaceuticals to enhance treatment outcomes for neuro-immune conditions. Their technology utilizes non-invasive digital interventions to improve brain connectivity and modulate immune biomarkers, optimizing the effectiveness of drug therapies.

GripAble develops digital therapy tools that utilize sensors to assess and train hand and arm movements, enhancing rehabilitation for physically impaired patients. By integrating engaging mobile games, GripAble improves patient adherence and outcomes while providing clinicians with objective progress tracking and documentation for optimal reimbursement.

DeepWell DTx combines FDA-cleared biofeedback technology with interactive gaming to provide over-the-counter digital therapeutics that target stress and hypertension. Their first game, Zengence, utilizes vocal meditation techniques to enhance vagus nerve activation, promoting resilience and reducing anxiety in players.

The startup develops a digital platform that utilizes virtual reality to deliver automated therapy modules for patients with stroke, dementia, Parkinson's, and cognitive impairments. This technology enhances the effectiveness and engagement of physiotherapy and rehabilitation, supporting patients in their recovery and complementing existing care plans.

The startup develops digital therapeutics that enhance brain health through personalized interventions delivered via smartphones. By integrating data from wearables, the platform enables users to monitor and improve cognitive function effectively.

The startup develops a personalized therapeutic music technology that utilizes real-time measurement and closed-loop algorithms to deliver tailored digital music therapy services. This technology aims to reduce stress and anxiety, enhance focus, and improve productivity for users in behavioral and neuropsychiatric health contexts.

Vitadio develops AI-driven digital therapeutics for type 2 diabetes, utilizing real-time feedback and personalized lifestyle modification to reverse insulin resistance. The platform enables users to achieve significant reductions in HbA1c and body weight, improving diabetes management without the side effects associated with traditional medications.

Oui Therapeutics is developing the world's first prescription digital therapeutic specifically designed to address suicide risk through evidence-based digital interventions. Their clinical trials aim to validate the efficacy of these therapeutics in reducing suicidal ideation and improving mental health outcomes.

Dana is a digital therapeutics platform that utilizes predictive intelligence and digital biomarkers to provide personalized mental health support for women during preconception, pregnancy, and early motherhood. The platform addresses the high rates of underdiagnosed and untreated mental health conditions, such as postpartum depression and anxiety, by offering tailored interventions and resources to improve maternal mental health outcomes.

AppThera is a digital therapeutics platform that enables healthcare providers to prescribe clinically validated mobile applications for managing chronic conditions such as diabetes and insomnia. By offering a streamlined selection of CE-marked therapies with proven efficacy, AppThera enhances patient adherence to treatment plans and improves overall quality of life.

Blue Note Therapeutics develops prescription digital therapeutics that utilize evidence-based behavioral interventions to improve patient outcomes in mental health. The company targets the challenges of treatment adherence and access to care by providing scalable, clinically validated solutions for patients managing mental health conditions.

Wellthy Therapeutics provides a cloud‑based Digital Therapeutics Operating System that enables biopharma firms, insurers, medical‑device manufacturers, and health systems to create and deploy regulated digital care programs for chronic diseases. The platform combines modular patient‑companion front‑ends with an ISO‑13485, GDPR and HIPAA‑compliant back‑end, offering AI‑driven analytics, remote monitoring, health‑coach support, and FHIR‑compatible APIs to capture real‑world data for clinical decision‑support and value‑based reimbursement.

The startup offers a digital physiotherapy platform that utilizes AI-driven assessments and real-time virtual sessions to provide personalized musculoskeletal care. This service enables immediate treatment and continuous adaptation to individual needs, eliminating traditional wait times and the necessity for in-person visits.

The startup develops a digital therapeutic technology that utilizes light stimulation to target specific photosensitive cells in the retina, modulating dopamine levels to regulate eye growth. This clinically validated therapy aims to slow the progression of myopia in children and adolescents.

Moovd develops digital therapy solutions, including the WeMind platform, which utilizes EMDR (Eye Movement Desensitization and Reprocessing) techniques to enhance therapeutic outcomes. The platform improves session efficiency for therapists and accelerates symptom reduction for clients, evidenced by a 49% faster decline in subjective units of distress (SUD).

SERG Technologies provides a digital therapeutics platform, PD.Ignite, that utilizes patented wearables and a centralized dashboard to monitor and manage Parkinson's Disease. This solution enables personalized care by adapting treatment plans based on real-time analytics, enhancing the quality of life for individuals with neurodegenerative movement disorders.

MetaMe Health develops FDA-cleared prescription digital therapeutics that utilize software applications to train the brain for managing gastrointestinal conditions. This approach provides patients with a non-pharmacological option to alleviate chronic pain and improve their quality of life through accessible mobile technology.

The startup offers a digital platform that provides personalized, clinically validated digital therapeutics for insomnia through mobile applications and wearable devices. By integrating psychology, mindfulness, and medical protocols, the platform enables users to effectively reduce and prevent insomnia with accessible, evidence-based interventions.

Develops platform-based digital therapeutics (DTx) and remote patient monitoring (RPM) solutions tailored for dermatology and allergology, combining clinical validation, machine learning, and real-world data integration. These CE-approved medical devices improve patient engagement and treatment adherence by providing personalized support, real-time monitoring, and actionable insights for healthcare providers.

BfB Labs develops evidence-based digital therapeutic games that empower children and young people to self-manage mental health challenges such as anxiety and stress. Their platform combines engaging gaming experiences with real-time data tracking, providing clinicians and educators with actionable insights to support youth mental health.

MiNDNET develops evidence-based digital therapeutics (DTx) and manages the approval process for digital health applications (DiGA) specifically for individuals with mental health conditions. By integrating these digital solutions into the existing healthcare system, MiNDNET enhances treatment accessibility and effectiveness for patients and healthcare professionals alike.

Sona is a digital therapeutics platform that utilizes neuroscience-backed music designed to enhance alpha and theta brain wave activity, promoting relaxation and improved mental health. The app provides personalized playlists to help users reduce stress, ease anxiety, and improve sleep quality through curated soundscapes created by Grammy-winning producers.

Mahana Therapeutics develops FDA-cleared digital therapeutics, including Mahana™ IBS and Mahana Tinnitus, which provide self-guided, smartphone-enabled programs for managing chronic gastrointestinal and tinnitus conditions. These clinically tested programs offer personalized physical and psychological support to improve patient well-being and enhance the patient-provider relationship.

The startup develops a diagnostics and digital therapeutics platform that integrates clinically validated diagnostic tools with digital health technologies for managing autoimmune diseases. By collaborating with research institutions and healthcare practitioners, the platform aims to enhance care management and service delivery for chronic health patients, ultimately reducing mortality and morbidity rates.

Renalis develops FDA-cleared Prescription Digital Therapeutics (PDTs) that provide evidence-based behavioral therapy for overactive bladder (OAB) in individuals assigned female at birth. Their mobile-enhanced platform delivers accessible and cost-effective treatment, improving patient outcomes for those experiencing OAB symptoms.

The startup develops a digital therapy platform that utilizes an immersive video game to treat major depressive episodes, particularly for patients who do not respond to traditional therapies. This approach aims to achieve measurable reductions in depressive symptoms and improvements in quality of life, with outcomes comparable to psychotherapy.

The startup develops a digital therapeutic device that utilizes biometric sensors and machine learning algorithms to monitor sleep patterns and detect the onset of traumatic nightmares in patients with post-traumatic stress disorder. By providing vibrotactile feedback, the device helps to arouse the sleeper, promoting better and more restful sleep.

SUSMED provides prescription‑grade digital therapeutic applications for chronic conditions such as insomnia, tinnitus, and chronic kidney disease, delivered via iOS and Android. It also offers a blockchain‑based clinical trial platform that records consent, randomization, and outcomes with immutable audit trails, complemented by machine‑learning analytics and FHIR‑compatible APIs for integration with EHRs and sponsor data systems. The solutions enable pharmaceutical companies, CROs, and healthcare providers to develop, monitor, and commercialize digital therapies within a compliant, cloud‑hosted environment.